
Prof. Peter Hellings discusses the interconnection between the pathophysiology, burden and clinical management of uncontrolled and/or severe CRSwNP
Dr. Sarina Elmariah explains the importance of neuroimmune crosstalk in the development of prurigo nodularis.
Dr. Lawrence Eichenfield describes the pathophysiology of atopic dermatitis and how type 2 inflammation may sensitize patients to atopic comorbidities.
Dr Donna Culton walks through the pathophysiology of type 2 inflammation in inflammatory skin diseases, using bullous pemphigoid as an example. Drs Eichenfield, Elmariah, and Hawkes join to discuss the role of type 2 inflammation across atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria, respectively.
An infographic exploring the pathophysiology of prurigo nodularis and the role of type 2 inflammation.

In this expert interview video focusing on topics from the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Christine Bangert discusses the epidemiology of AD in children and the role of type 2 cytokines in driving the pathophysiology of the disease

Explore the role of interleukin (IL)-33 in chronic obstructive pulmonary disease (COPD) pathophysiology and its potential as a therapeutic target.

Join Dr. Jason Hawkes as he explains the importance of type 2 inflammation in chronic spontaneous urticaria.
This symposium delves into the pivotal role of type 2 inflammation in diverse skin conditions, including atopic dermatitis, prurigo nodularis, chronic spontaneous urticaria, and bullous pemphigoid. It highlights both shared and distinct disease mechanisms and patient burdens, providing crucial insights for optimizing clinical management strategies through a series of engaging panel discussions with Drs Eichenfield, Elmariah, Culton, and Hawkes.

Dr. Amy Paller describes potential biomarkers of subclinical control at EADV 2025
Explore the role of type 2 inflammation in the production of mucus plugs in asthma and the effects these plugs can have on patients.

Professor Klaus Rabe delves into the intricate inflammatory pathways and cellular mechanisms that drive the development and progression of COPD.